Introduction
Autologous hematopoietic SCT (auto-HSCT) represents potentially curative therapy for patients with Hodgkin's lymphoma (HL) and intermediate-grade non-Hodgkin's lymphoma (NHL) who relapse after conventional chemotherapy. [1] [2] [3] Patients with low-grade NHL also can benefit from auto-HSCT by attaining prolonged remissions after transplantation. [4] [5] [6] Unfortunately, relapse remains the most common cause of failure after auto-HSCT and the prognosis of such patients is poor. [7] [8] [9] As thousands of HL and NHL patients undergo auto-HSCT each year, clinicians frequently face the dilemma of how to manage those patients who relapse. Second transplants, autologous or allogeneic, frequently are considered for patients who relapse after auto-HSCT. The studies published to date often include many lymphoma subtypes and report the results in aggregate, frequently making it difficult to reach firm conclusions about the role of second transplants in the management of particular types of lymphoma. Despite this limitation, an increasing body of work is available that can contribute to planning the management of this unfortunate group of patients. This article reviews the results of second transplants for lymphoma patients who relapse after auto-HSCT.
Therapeutic options for patients with lymphoma who relapse after autologous transplantation
To put into context the use of second transplants for patients who relapse after auto-HSCT, it is necessary to briefly discuss other therapeutic alternatives for this population of patients ( Table 1 ). The use of the MoAb, rituximab, is an attractive therapeutic alternative for patients with lymphoma who relapse after auto-HSCT because of its low incidence of side effects. The therapeutic activity of rituximab in patients previously treated with auto-HSCT was first observed in the pivotal trial of rituximab. 10 In this trial, patients whose previous therapy included auto-HSCT had a significantly higher response rate than those who had not undergone transplantation (78 vs 43%, respectively). Small cohorts of intermediateand low-grade NHL patients who relapsed after auto-HSCT treated with rituximab as part of the salvage therapy have been reported. [11] [12] [13] Overall, more than half of the patients responded to rituximab, although most of the responses were partial. In two reports, survival was longer for patients who received rituximab compared with patients who did not receive Ab therapy for post-transplant relapse. 8, 9 Many of these reports, however, were published before the widespread use of rituximab as part of the initial lymphoma therapy.
Despite the availability of two radioimmunotoxins for several years, there is limited information regarding the use of radioimmunotherapy in patients with lymphoma who relapse after auto-HSCT. Recently, Vose et al.
14 reported the use of yttrium-90 ibritumomab tiuxetan in 19 patients with B-cell NHL who progressed after auto-HSCT. These patients were treated with a cohort-specific yttrium-90 ibritumomab tiuxetan dose. Approximately 60% of the patients had diffuse large B-cell lymphoma and one-third had follicular lymphoma. Patients had been treated with a median of three previous therapies (range [1] [2] [3] [4] [5] [6] [7] [8] [9] and the median time after auto-HSCT was 28 months. The authors determined that a 0.2 mCi/kg ibritumomab tiuxetan dose was safe and effective for this population of heavily pretreated patients and half attained a response. At a median follow-up of 37 months, the 1-year EFS and OS rates were 26 and 57%, respectively. Disease histology, previous treatment history, age, gender or age-adjusted International Prognostic Index were not significant predictors of treatment outcome. These results are encouraging but longer follow-up is needed to determine the long-term efficacy of this approach.
The use of radiation as salvage therapy for patients who relapse after auto-HSCT is limited by the fact that many patients experience systemic relapse of the lymphoma. Furthermore, patients who have received TBI frequently cannot receive additional radiotherapy because they have reached the maximal tolerated doses of radiation to the vital organs. Despite these limitations, it is of interest that in one of the earliest reports of patients who relapsed after auto-HSCT, one-fourth of the patients who remained off therapy and without progressive disease received involvedfield radiation as the only salvage therapy. 15 This experience suggests that radiation therapy is a viable alternative for the limited number of patients with localized relapse after auto-HSCT.
Several chemotherapeutic salvage regimens for HL patients, often vinca alkaloid-based, have been well tolerated by patients who have relapsed after their auto-HSCT. 16, 17 Only a small proportion of these HL patients attain prolonged remissions after this therapy.
Given the limitations of currently available therapies, lymphoma patients who experience tumor progression after auto-HSCT should be encouraged to participate in clinical trials exploring the use of new drugs or novel therapeutic approaches. Promising therapeutic alternatives such as fostamatinib disodium, a spleen tyrosine kinase inhibitor, 18 and ofatumumab, a novel anti-CD20 Mb, 19 are being investigated. Table 2 illustrates some novel and investigational agents being studied in patients with lymphoma. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Unfortunately, many phase I and II studies exclude patients previously treated using transplantation because of concerns regarding the patient's hematological reserve and their previous extensive treatment. In addition, many other patients do not have access to experimental studies because of logistic or geographic limitations.
Second autologous transplants in lymphoma patients who relapse after a previous autologous transplant As illustrated in Table 3 , the earliest reports of second auto-HSCT for lymphoma patients who relapse or progress after an initial autotransplant were single-institution studies with small numbers of patients. 8, 15, [31] [32] [33] Despite this limitation, several conclusions can be reached by analyzing these early studies. First, the treatment-related mortality (TRM) was higher than expected after an initial auto-HSCT and ranged from 11 to 40%. The higher incidence of secondary tumors in long-term survivors after second auto-HSCT also was described in one of the studies with the longest posttransplant follow-up. 33 Despite the higher TRM associated with the second auto-HSCT, a select group of patients attained prolonged remissions.
The European Blood and Bone Marrow Registry described one of the largest series of second auto-HSCT. 34 Twenty lymphoma patients underwent second auto-HSCT from 1982 to 1995. The median time interval between transplants was 17 (range 4-83) months. Forty per cent of patients (approximately half HL and high-grade NHL) remained in CR for 4-36 months at the time of the report. Low-grade patients did not benefit as much from this approach as only one of five patients remain in CR.
The European Blood and Bone Marrow Registry study also reported on patients who underwent a second auto-HSCT as therapy for partial or no response after initial auto-HSCT. As expected, this cohort of patients had a worse outcome than patients who relapsed after their first auto-HSCT, that is, only 2 of 10 remained in CR at 19 and 31 months after the second transplant. Most refractory lymphoma patients died of progressive disease despite undergoing a second autotransplant. In this study, two 35 Approximately half the patients had HL and the remainder intermediate-grade NHL. The second auto-HSCT was carried out 41 year after the first transplant in 82% of patients. Fifty-eight per cent of the patients who underwent second auto-HSCT had sensitive disease at the time of the second transplant (18% in CR). The 1-year TRM was 18%, similar to the European Blood and Bone Marrow Registry study, whereas 5-year PFS and OS were estimated at 30%. Three patients (8%) developed fatal secondary myelodysplastic syndromes. The strengths of this study include the large number of patients and the long median follow-up of 6 years after the second auto-HSCT. It is important to recognize that the population described in this study is highly selected given the relatively long time interval between transplants and the fact that 85% of the patients were able to undergo successful stem cell harvests before the second auto-HSCT.
Streetly et al. 36 approached the problem of relapse after second auto-HSCT using the immunomodulatory agents, CYA and IFN-g, to induce a graft-vs-tumor (GVT) effect in 10 patients (7 NHL and 3 HL). Histological changes consistent with cutaneous GVHD were observed in three patients. At a median follow-up of 20 months, five patients remained in CR; there was no obvious relationship between the development of GVHD and second transplant outcome.
In summary, only a small number of lymphoma patients have undergone second auto-HSCT as therapy for previous auto-HSCT failures. The limited number of patients reported and the fact that most subjects had successful hematopoietic stem cell harvest for the second transplant reflects the highly selected nature of this population. One can conclude that the TRM for second transplants is much higher than that after the first auto-HSCT, but the durable survival rates of 20-40% compare favorably with historical controls using conventional salvage regimens. Relapse and treatment-related malignancies remain the major challenges for patients who undergo second autotransplants. 37 Patients most likely to benefit from this approach are those with chemotherapy-sensitive lymphoma and those in whom there is a prolonged time interval between transplants. This strategy should be investigated further given the encouraging results observed in recent studies and the limited options available to these patients.
Allo-HSCT after auto-HSCT failure
Allogeneic hematopoietic (allo-HSCT) increasingly has been used as salvage therapy for lymphoma patients who relapse after auto-HSCT. Potential advantages of allo-HSCT over auto-HSCT include use of a tumor-free graft and immunemediated GVT effect.
Myeloablative conditioning allo-HSCT
The first reports for patients who underwent allo-HSCT after auto-HSCT failure used myeloablative conditioning regimens (Table 4) . 15, 31, [38] [39] [40] [41] [42] [43] [44] [45] [46] Many publications come from single-institution studies involving small numbers of patients. 15, 31, 38 Most communications describe a TRM as high as 80% and a high risk of GVHD; however, selected patients attained durable remissions without the need for further therapy.
Tsai et al. 39 described 20 patients from a consortium of institutions, including 9 HL and 5 NHL who underwent myeloablative conditioning allo-HSCT after auto-HSCT failure. BU-based conditioning regimens were used in 12 patients, and 4 patients received TBI as part of the preparation. As in previous studies, 90% of the patients developed severe acute GVHD and most died early due to transplant-related toxicities. Only two patients remained alive at the time of the report, each of them with HL and follicular lymphoma. The authors concluded that alternative therapies or investigational approaches should be considered for patients who relapse after autologous transplantation given the high TRM of this procedure. A preliminary communication by Bierman et al. 40 summarized the experience of two institutions that used myeloablative conditioning allo-SCT after the auto-HSCT failure. Nine patients had NHL and six had HL. All allo-SCT donors were HLA-identical siblings and the median age was 35 years. Median interval between transplants was 1.8 years. Forty-four per cent of patients died within 100 days after allo-SCT. Despite the high TRM, 2-year OS and disease-free survival (DFS) after transplant were estimated at 36%. In this experience, patients who underwent allo-SCT 41 year after their auto-HSCT had OS and DFS estimated at 42%. In contrast, patients who underwent allo-SCT o1 year after their autologous transplant had an estimated DFS of 20%. The authors concluded that this methodology should be considered if there has been a long time interval before auto-HSCT relapse. The Seattle group reported their experience for myeloablative allo-SCT after auto-HSCT failure for hematological malignancy. 41 They described 59 patients including 18 with lymphoma. They used TBI-containing myeloablative conditioning regimens for the allo-SCT in patients who received chemotherapy-based conditioning regimens for the auto-HSCT. If patients received TBI during the initial transplant, only chemotherapy was given for the allograft. As in previous reports, 2-year TRM was extremely high at 78%. The few lymphoma patients who did not die of transplant-related complications relapsed after allo-SCT; at the time of the report, there were no long-term survivors after myeloablative allo-SCT, leading the authors to conclude that other therapies should be explored, including reduced-intensity conditioning (RIC) allogeneic transplants.
In the only report exclusively describing HL patients, Cooney et al. 45 reported 10 consecutive patients treated with myeloablative allo-SCT and early withdrawal of immunosuppression for relapse after auto-HSCT. BEAM (BCNU, etoposide, cytarabine and melphalan), a lessintensive conditioning regimen usually reserved for patients undergoing auto-HSCT, was given. There were no treatment-related deaths at 100 days after transplant, despite the fact that four patients received grafts from matched unrelated donors. At the time of the report, nine patients were alive, seven in CR. A limitation of this study is the short follow-up (median 1 year) after allo-SCT.
As illustrated above, most series of lymphoma patients who underwent myeloablative allo-SCT after auto-HSCT failure are small in numbers and show conflicting results. The International Bone Marrow Transplant Registry analyzed the results of myeloablative allogeneic stem transplantation after auto-HSCT failure. 46 One hundred and fourteen HL and NHL patients transplanted between 1990 and 1999 were reported according to the Working Formulation histology. 47 Median age was 34 years and 40% of patients received transplants from haploidentical or unrelated donors. In contrast to previous studies, TRM was 22%, lower than previously reported, despite the high proportion of alternative donors. In contrast to previous studies, the incidence of acute GVHD was only 29% at 100 days and the incidence of chronic GVHD was 11% at 1 year post-transplantation. Three-year probabilities of OS and PFS were encouraging at 33 and 25%, respectively. With prolonged follow-up, nearly all patients experienced disease progression and 5-year probabilities for OS and DFS were 24 and 5%, respectively. There was no significant difference in the outcome between HL and NHL or between low-grade or intermediate-grade lymphoma. CR at the time of allo-SCT and use of TBI in patients with NHL were associated with lower rates of disease progression and higher rates of OS. Of interest, the time interval between transplants did not predict for prolonged survival in this analysis. Despite the relatively large number of patients analyzed, a relationship between the development of GVHD and prolonged survival could not be established. The authors concluded that myeloablative allo-SCT can result in prolonged survival for some patients who relapse after auto-HSCT but usually it is not curative. They also concluded that the patients most likely to benefit from this approach were those with HLA-matched sibling donors, in remission at the time of allo-SCT and with good performance status at the time of allo-SCT. This study illustrates the importance of long-term follow-up in the interpretation of studies using allo-SCT as salvage therapy for patients who relapse after auto-HSCT. One can conclude that despite a lower rate of treatmentrelated deaths observed in recent studies, the TRM of lymphoma patients who undergo myeloablative allo-SCT after auto-HSCT failure remains high. A limitation of the available studies is the low patient number and limited follow-up of those treated with this approach. Nevertheless, it can be concluded from the largest studies published to date that myeloablative allo-SCT can result in prolonged survival in patients who relapse after auto-HSCT but only a small proportion, B5%, appear cured of lymphoma. As in the case of second autotransplants, the best results have been obtained in patients who have sensitive disease at the time of transplantation. Owing to the limited number of patients and the high TRM observed in most studies, it has been difficult to determine the effect of the GVT effect on the outcome of this population of patients.
Non-myeloablative or RIC allo-HSCT
The number of reports of non-myeloablative or RIC allo-SCT for patients who relapse after auto-HSCT (Table 5) have burgeoned recently. [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] The rationale behind this strategy is to decrease the high TRM observed after myeloablative allo-SCT, though preserving the GVT effect. In addition, RIC allo-SCT allows patients with significant coexistent medical problems to undergo allo-SCT. Nagler et al. 48 reported a small series of 12 hematological malignancy patients (including five lymphomas) who underwent RIC allo-SCT as therapy for disease progression after auto-HSCT progression, one of the earliest studies using this approach. Patients who did not develop GVHD were given donor-lymphocyte infusions to achieve full chimerism and to optimize GVT effect. The median time interval between transplants was 2 years. None of the five lymphoma patients died of transplant-related complications and two subjects remained alive, one disease free at 20 months after transplant.
In one of the largest studies to date, Branson et al.
52
reported 25 lymphoma patients who underwent HLAmatched related RIC allo-SCT after auto-HSCT failure.
The conditioning regimen consisted of Campath, fludarabine and melphalan. Eight patients experienced grade I/II GVHD but no grade III/IV GVHD was observed in this study. Estimated TRM was 8 and 20% at 100 days and 14 months, respectively. The low incidence of GVHD allowed the investigators to treat some patients with donorlymphocyte infusion after allo-SCT. At a median followup of 14 months, the actuarial PFS was 50%.
A consortium of Spanish institutions reported their experience using RIC allo-SCT after auto-HSCT failure that included 22 lymphoma patients. 53 The conditioning regimens were fludarabine-based. At 1-year median followup, the 1-year TRM for all patients was 24%. The 1-year OS and DFS were 63 and 57%, respectively. Adverse prognostic factors in this report included refractory or progressive disease, low performance status and having received GVHD prophylaxis consisting solely of CYA. There were no deaths in the cohort of patients who did not have any of the adverse prognostic factors. The authors concluded that adults who fail auto-HSCT can be salvaged with RIC regimens and allo-SCT, although they emphasized that patient selection has a profound influence in the outcome.
In two separate reports, the MD Anderson Cancer Center has described their experience using RIC allo-SCT for lymphoma patients who relapse after auto-HSCT. 57, 58 The first report, describing some of the best outcome data reported to date and also with long follow-up, included 20 consecutive NHL patients (10 patients with diffuse large cell lymphoma, 5 with mantle cell lymphoma and 5 with follicular lymphoma). 57 Patients were required to have stable or chemosensitive disease in order to be eligible to undergo allo-SCT. The median interval between transplants was 2 years. Most patients received fludarabine, CY and rituximab conditioning, and tacrolimus and methotrexate were used for GVHD prophylaxis. With a median follow-up of 2 years, the estimated 3-year PFS was an encouraging 95%. Only one patient experienced grade II GVHD, the highest grade of GVHD observed and only a single death (fungal infection) occurred. One patient experienced disease progression after allo-SCT but responded to donor-lymphocyte infusion. The authors concluded that RIC allo-SCT is an effective option for lymphoma patients who have stable or chemosensitive disease after auto-HSCT. Possible explanations for the good outcome observed in this study include the requirement for patients having stable or responsive disease at the time of allo-SCT and the prolonged interval between transplants.
The second MD Anderson Cancer Center Group report describes their experience in 40 relapsed or refractory HL patients who underwent HLA-identical sibling or matched unrelated donor allo-SCT using RIC. 58 They used two conditioning regimens, fludarabine-CY with or without ATG, or a more intensive fludarabine and melphalan combination; GVHD prophylaxis consisted only of tacrolimus. Day 100 and 18-month cumulative TRM were 5 and 22%, respectively. At the time of their report, 24 (60%) patients were alive in CR with a median follow-up of 13 months. In this study, the patients who received the fludarabine-melphalan conditioning regimen had longer OS and experienced a trend toward better PFS. As in previous studies, half the deaths were attributed to progressive disease and the other half to transplant-related complications. This report represents the largest experience to date using this strategy for HL patients who failed an auto-HSCT.
A consortium of institutions led by the Seattle group separately reported their experience using this approach. 55, 59 The first report included 34 lymphoma patients who underwent allo-SCT after conditioning regimen with 2 Gy TBI with or without fludarabine. HLA-matched siblings and unrelated donors were used as the stem cell donor source. GVHD prophylaxis consisted of mycophenolate mofetil and CYA. The median interval between transplants was 22 months. TRM at 100 days and 1 year was 10 and 20%, respectively. With a median follow-up of 1 year, 1-year estimates of OS and PFS were 49 and 28%, respectively. Untreated disease at the time of allo-SCT increased the risk of death. 55 An update of this consortium's experience was recently published and additional patients were included. 59 In all, 85 of the 147 patients had lymphoma and the results were reported in aggregate (including all diagnoses) by the graft source; the 3-year probability of TRM, relapse and OS were 32, 48 and 27%, respectively, for related recipients. For unrelated recipients, the 3-year probability of TRM, relapse and OS were 28, 44 and 44%, respectively. The best outcomes were observed in patients with indolent lymphoma and mantle cell lymphoma who had a 3-year PFS probability of 57%. The worst outcome was observed in HL patients who had a 3-year PFS probability of only 8%. Patients in partial or CR at the time of RIC allo-SCT enjoyed lower risks of relapse and progression and had better OS. Acute GVHD negatively affected OS but the presence of chronic GVHD resulted in lower risks of relapse and progression. Of importance was the fact that unrelated and related donor transplants had similar outcomes. More recently, this group separately reported their experience for diffuse large cell B-cell lymphoma patients who failed (75%) or were ineligible for auto-HSCT. Using the same conditioning regimens, 3-year estimated OS and PFS were 45 and 35%, respectively. 61 Authors from a consortium of United Kingdom institutions analyzed the role of RIC allo-SCT for HL patients who relapsed after auto-HSCT. 60 They compared patient outcome for RIC allo-SCT after autotransplant failure with a historical control group who relapsed before the advent of this salvage allograft approach. The historical controls had to respond to salvage therapy and live for at least a year after relapse, factors which would have made them eligible for RIC-allo SCT. The OS rate after autotransplant was 65% at 5 years in the RIC allo-SCT vs 15% in the historical cohort.
The largest analysis of lymphoma patients who underwent RIC allo-SCT after auto-HSCT failure recently was reported by the Center for International Blood and Marrow Transplant Research. 62 The study comprised 267 patients transplanted between 1996 and 2006. The median age of this cohort was 52 years and 56% had intermediate-grade NHL. Approximately 17% had lowgrade NHL and a quarter had mantle cell lymphoma. Twothirds of the patients had chemosensitive disease at the time of the RIC allo-SCT; 20% received 2 Gy of TBI as part of the conditioning regimen. Despite a 42% 3-year TRM, 5-year OS and DFS were estimated at 28 and 19%, respectively. These results compared favorably with the use of myeloablative allo-SCT in lymphoma patients who relapsed after auto-HSCT. Factors associated with lower relapse risk or death included a Karnofsky performance score 490%, interval between transplants 424 months, TBI as part of the conditioning regimen and CR at the time of RIC allo-SCT. Of interest, acute GVHD decreased the risk of relapse supporting a GVT effect.
The results of the above studies illustrate that RIC allo-SCT may be associated with substantial TRM but durable remissions can be attained in a higher proportion of patients compared with conventional therapy. Outcomes of multi-institutional trials show 30-50% 3-year DFS and an observational database registry study projects a 20% 5-year DFS. These results compare favorably with the use of myeloablative allo-SCT after autotransplant failure. The limited number of patients studied to date makes it difficult to determine what types of lymphoma can benefit the most from RIC allo-SCT. In addition, the role of the GVT effect has been difficult to establish in some studies given the low number of patients studied. The major limitation of the current studies is the short follow-up after RIC allo-SCT. As illustrated by the International Bone Marrow Transplant Registry study, a continuous pattern of relapse can affect the long-term results of this therapeutic strategy dramatically. 46 Despite the lack of long-term results, RIC allo-SCT remains the most promising therapy for selected patients with lymphoma who relapse after auto-HSCT. These findings are particularly encouraging when considering that advanced age patients or those with significant comorbidities have become eligible for this therapeutic approach. Summary and suggested treatment strategies Despite the effectiveness of auto-HSCT as therapy for recurrent lymphomas, disease relapse remains its major limitation and the prognosis of patients who relapse after this modality generally is poor even when conventional salvage regimens are used. The use of second autologous transplants has been studied in a minority of patients but recent registry data suggest that this strategy could represent a good therapeutic alternative for selected patients (responsive disease and prolonged time interval between transplants). This therapeutic strategy should be further studied given the encouraging results reported recently.
Allo-SCT is an attractive option for relapse after auto-HSCT because of the lack of graft tumor contamination and GVL effect. Unfortunately, long-term studies suggest that although myeloablative allo-SCT can induce prolonged remissions in such patients, o5% can be considered cured of their lymphoma. RIC allogeneic transplantation has been used increasingly and results from single and multi-institutional trials using this strategy are promising. Long-term studies, however, will be necessary to determine the proportion of patients cured after this procedure.
On the basis of the information available to date, we suggest a strategy for managing patients who relapse after auto-HSCT recognizing that a great deal of information is necessary before we can answer many of the clinical dilemmas pertaining to this complex population of patient ( Figure 1) . Patients who experience lymphoma relapse less than a year after autotransplantation should be considered for investigational studies as these subjects tend to fare poorly after second transplantation of any type. Patients who relapse 41 year after autotransplantation should be treated with salvage therapy; those who have sensitive disease and an HLA-compatible donor (related or unrelated) should be considered for RIC allo-SCT (assuming good visceral organ function). Patients with chemosensitive disease who do not have an HLA-compatible donor or are not physically fit for RIC allo-SCT should be considered for a second autotransplant if sufficient hematopoietic stem cells can be harvested. Patients who prove to have chemoresistant disease after salvage therapy should be considered for investigational protocols as most do not benefit from second transplants.
The key questions that should be addressed in future studies include the optimal selection of patients, the development of conditioning regimens that further decrease TRM and strategies that enhance the GVT effect. Other important areas of investigation include the optimal use of donor-lymphocyte infusion in patients who do not respond to this therapeutic strategy and the development of better supportive care during this demanding therapy.
